Watch BBLG. Know when insiders buy.
One email the day a filing lands. Free.
BBLG
Bone Biologics Corp
0.56
−0.01 −1.41%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$2.9MNET CASH —52W 0.55 – 2.79SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$808K | −$774K | — | -0.43 | −$518K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$805K | −$766K | — | -0.43 | −$804K | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$733K | −$685K | — | -0.14 | −$715K | — | — | Mar 2 |
| Q3 2025 · Sep 30 | — | — | — | −$715K | −$667K | — | -0.37 | −$591K | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$748K | −$741K | — | -1.33 | −$459K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$1M | −$1M | — | -1.92 | −$926K | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.6M | −$1.5M | — | 0.13 | −$1.4M | — | — | Mar 2 |
| Q3 2024 · Sep 30 | — | — | — | −$951K | −$941K | — | -14.21 | −$572K | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$810K | −$784K | — | -4.02 | −$896K | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$904K | −$866K | — | -1.31 | −$1.3M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.2M | −$1.5M | — | 3.39 | −$2M | — | — | Feb 26 |
| Q3 2023 · Sep 30 | — | — | — | −$2.1M | −$1.9M | — | -4.90 | −$2.6M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$3.2M | −$3.1M | — | -2.65 | −$2.7M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$4.2M | −$4.1M | — | -28.96 | −$4.1M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$9.4M | −$8.9M | — | -34.01 | −$9.6M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$3.7M | −$1.5M | — | -31.15 | −$3.6M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$1.1M | −$1.6M | — | -0.35 | −$1.2M | — | — | — | — |
| FY2020 · to Dec 31 | $1.1B | — | −$825K | −$1.8M | -0.2% | -0.63 | −$427K | — | — | — | — |
Every number comes from Bone Biologics Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.